Previous 10 | Next 10 |
2024-06-05 05:10:00 ET Summary High vacancies, increasing taxes and utilities and heavy debt loads are causing some property owners to simply walk away from significant buildings. Pfizer rose to $61 in December 2020 shortly after its vaccine came to market; it now looks decidedly ...
2024-06-04 13:22:09 ET Moderna, Inc. (MRNA) Moderna Oncology Investor Event June 3, 2024 07:15 PM ET Company Participants Stephen Hoge - President Kyle Holen - Head of Development, Therapeutics and Oncology Michelle Brown - Vice President, INT Oncology Rose L...
2024-06-03 10:01:08 ET Moderna ( NASDAQ: MRNA ) and Merck ( NYSE: MRK ) announced on Monday that their high-risk skin cancer vaccine, which is in combination with Keytruda, showed meaningful improvement in survival rate of patients.... Read the full article on Seeking ...
At a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis or death by 62% compared to KEYTRUDA alone in these patients The 2.5-year recurrence-free surviv...
2024-06-03 06:07:00 ET The shortened trading week that ended on May 31 was a strange one for the vaccine developer Moderna (NASDAQ: MRNA) . Biotech stocks generally rise after a product they spent years developing earns marketing approval, but this isn't what happened. On Friday...
2024-06-03 04:50:00 ET Moderna (NASDAQ: MRNA) jumped into the limelight when it started developing a coronavirus vaccine candidate. And the stock soared as the vaccine raced across the finish line and went on to bring in billions of dollars in earnings. But in later pandemic day...
2024-06-02 16:00:49 ET More on the markets Going Into June, SPY Or VXF, Which Is The Better Buy? (Technical Analysis) SPY: 2 Options To Balance Out A Highly Concentrated Index Bitcoin's Fading Action Is A Huge Warning For Stock Market Liquidity Stocks most lo...
2024-05-31 23:06:08 ET Moderna, Inc. (MRNA) Bernstein's 40th Annual Strategic Decisions Conference May 31, 2024 10:00 PM ET Company Participants Stephane Bancel - CEO Conference Call Participants Courtney Breen - Bernstein Presentation Courtney ...
2024-05-31 15:30:03 ET RBC Capital analyst issues OUTPERFORM recommendation for MRNA on May 31, 2024 01:55PM ET. The previous analyst recommendation was Outperform. MRNA was trading at $141.9 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-05-31 15:00:07 ET Luca Issi from RBC Capital issued a price target of $160.00 for MRNA on 2024-05-31 13:55:00. The adjusted price target was set to $160.00. At the time of the announcement, MRNA was trading at $141.83. The overall price target consensus is at $158.4...
News, Short Squeeze, Breakout and More Instantly...
CAMBRIDGE, MA / ACCESSWIRE / July 10, 2024 / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Thursday, August 1, 2024 to report its second quarter 2024 financial results, and provide a corporate update. A live webcast of the c...
CAMBRIDGE, MA AND OSAKA, JAPAN / ACCESSWIRE / July 8, 2024 / Moderna, Inc. (Nasdaq:MRNA) and Mitsubishi Tanabe Pharma Corporation today announced that the companies have entered into a joint agreement regarding the co-promotion of Moderna's mRNA respiratory vaccine portfolio in Japan, including ...
CAMBRIDGE, MA / ACCESSWIRE / July 2, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA-based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical...